Johnson & Johnson Pivotal Study Of Seltorexant Shows Clinically Meaningful Improvement In Depressive Symptoms And Sleep Disturbance Outcomes
Portfolio Pulse from Benzinga Newsdesk
Johnson & Johnson's pivotal Phase 3 study of Seltorexant shows significant improvement in depressive symptoms and sleep disturbances in patients with major depressive disorder (MDD) with insomnia. The study met all primary and secondary endpoints. Additionally, positive results for SPRAVATO® (esketamine) nasal spray were presented, showing rapid and sustained efficacy in treatment-resistant depression (TRD).
May 29, 2024 | 4:18 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Johnson & Johnson's Phase 3 study of Seltorexant shows significant improvement in depressive symptoms and sleep disturbances in MDD patients. Positive results for SPRAVATO® nasal spray in TRD were also presented.
The successful Phase 3 study of Seltorexant and positive results for SPRAVATO® indicate potential new treatment options for MDD and TRD, which could lead to increased revenue and positive investor sentiment for Johnson & Johnson.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100